WithdrawnNot Applicable

Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib

Stopped: sponsor withdrew funding

United States0Started 2026-01-01

Plain-language summary

The purpose of this study is to evaluate the repeatability of magnetic resonance imaging (MRI) in patients with isocitrate dehydrogenase 1 (IDH1) mutant (mIDH1) low-grade diffuse glioma \[World Health Organization (WHO) grade 2\] who are receiving off-label ivosidenib.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed consent prior to beginning specific protocol procedures
✓. Scheduled for contrast-enhanced magnetic resonance imaging (MRI) as part of clinical care
✓. Histologically IDH1 mutant low-grade glioma (WHO grade 2) and actively receiving ivosidenib
✓. Active patient treatment or evaluations at the Preston Robert Tisch Brain Tumor Center at Duke
✓. Age ≥18 years and ≤70 years
✓. Karnofsky performance index ≥70%
✓. Primary treating physician approval

What they're measuring

Repeatability

Timeframe: 1 year

Trial details

NCT IDNCT06648473

SponsorDuke University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-01

View on ClinicalTrials.gov More Low Grade Glioma of Brain trials